Keyphrases
Biological Treatment
100%
Rapid Response
100%
Severity Index
100%
Moderate-to-severe Psoriasis
100%
Psoriasis Severity
100%
Psoriasis Area
100%
Area Index
100%
Comprehensive Investigation
100%
Frequentist Network Meta-analysis
100%
Ixekizumab
62%
Brodalumab
50%
Dermatology Life Quality Index
37%
Secukinumab
37%
Treatment Effect
25%
Adalimumab
25%
Etanercept
25%
Ustekinumab
25%
Frequentist
25%
Guselkumab
25%
Risankizumab
25%
Quality of Life
12%
Infliximab
12%
Adult Patients
12%
Response Rate
12%
Systematic Literature Review
12%
Sensitivity Analysis
12%
Quality Measures
12%
Relative Effect
12%
Index Score
12%
Rapid Treatment
12%
Clinical Benefit
12%
Psoriasis
12%
Tumour Necrosis Factor Inhibitor (TNFi)
12%
Interleukin-12 (IL-12)
12%
Interleukin-17 (IL-17)
12%
Double-blind Randomized Controlled Trial
12%
Eli Lilly
12%
Interleukin-23 (IL-23)
12%
Certolizumab Pegol
12%
Effect Estimates
12%
Rapid Improvement
12%
Treatment Selection
12%
Biologic Therapy
12%
Bayesian Analysis
12%
Tildrakizumab
12%
PASI90
12%
Treatment Ranking
12%
Baseline Effect
12%
Medicine and Dentistry
Network Meta-Analysis
100%
Psoriasis Vulgaris
100%
Psoriasis Area and Severity Index
100%
Ixekizumab
62%
Brodalumab
50%
Psoriasis
37%
Dermatology Life Quality Index
37%
Secukinumab
37%
Adalimumab
25%
Treatment Effect
25%
Biological Product
25%
Etanercept
25%
Ustekinumab
25%
Guselkumab
25%
Risankizumab
25%
Quality of Life
12%
Randomized Controlled Trial
12%
Systematic Review
12%
Infliximab
12%
Biological Therapy
12%
TNF Inhibitor
12%
Interleukin 17
12%
Interleukin 12
12%
Certolizumab Pegol
12%
Interleukin 23
12%
Tildrakizumab
12%
Immunology and Microbiology
Ixekizumab
100%
Brodalumab
80%
Secukinumab
60%
Etanercept
40%
Biological Product
40%
Adalimumab
40%
Ustekinumab
40%
Risankizumab
40%
Guselkumab
40%
Infliximab
20%
Interleukin 17
20%
TNF Inhibitor
20%
Interleukin 12
20%
Interleukin 23
20%
Tildrakizumab
20%
Certolizumab Pegol
20%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Psoriasis Vulgaris
100%
Ixekizumab
45%
Brodalumab
36%
Secukinumab
27%
Etanercept
18%
Biological Product
18%
Adalimumab
18%
Ustekinumab
18%
Guselkumab
18%
Risankizumab
18%
Randomized Controlled Trial
9%
Tumor Necrosis Factor Inhibitor
9%
Infliximab
9%
Interleukin 17
9%
Interleukin 12
9%
Interleukin 23
9%
Certolizumab Pegol
9%
Tildrakizumab
9%